Kurzfassung

This proposal suggests to study INCB01158-mediated inhibition of myeloid-derived suppressor cell (MDSC)-expressed arginase as a novel treatment approach for multiple myeloma. INCB01158 will be tested (i) as monotherapy, (ii) in combination with the established anti-myeloma agents daratumumab and pomalidomide/dexamethasone and (iii) the checkpoint inhibitor pembrolizumab. Our unique experimental system involves MM patient-derived myeloma antigen-specific T cells as well as MDSCs.